Litcius/Paper detail

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study

Bob T. Li, Funda Meric‐Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Philippe Aftimos, Ian Anderson, Giuseppe Curigliano, Giuseppe Curigliano, Maitri Kalra, Do‐Youn Oh, Joon Oh Park, Sophie Postel‐Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Ann Smith, Karime Kalil Machado, Cristina Saura, Cristina Saura, Bob T Li, Bob T Li, Funda Meric-Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Philippe Aftimos, Ian Anderson, Giuseppe Curigliano, Maria de Miguel, Maitri Kalra, Do-Youn Oh, Joon Oh Park, Sophie Postel-Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Ann Smith, Karime Kalil Machado, Cristina Saura

2024The Lancet Oncology102 citationsDOI

Topics & Concepts

TrastuzumabDestiny (ISS module)OncologyInternal medicineCancer researchMaximum tolerated doseMedicineCancerBreast cancerPhysicsAstronomyHER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsPeptidase Inhibition and Analysis